We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05502393
Recruitment Status : Recruiting
First Posted : August 16, 2022
Last Update Posted : August 16, 2022
Information provided by (Responsible Party):
Shanghai Junshi Bioscience Co., Ltd.

Tracking Information
First Submitted Date  ICMJE August 10, 2022
First Posted Date  ICMJE August 16, 2022
Last Update Posted Date August 16, 2022
Actual Study Start Date  ICMJE July 26, 2022
Estimated Primary Completion Date July 31, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 14, 2022)
  • MTD [ Time Frame: Up to approximately 12 months from first patient in. ]
    Determine maximum tolerated dose (MTD, if possible)
  • RP2D [ Time Frame: Up to approximately 24 months from first patient in. ]
    Recommended phase II dose (RP2D) for JS107 monotherapy and combination therapy
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: August 14, 2022)
  • Drug concentrations [ Time Frame: Up to approximately 24 months from first patient in. ]
    Drug concentrations in individual subjects at different time points after dosing
  • Immunogenicity [ Time Frame: Up to approximately 24 months from first patient in. ]
    Incidence of anti-drug antibody (ADA) and/or neutralizing antibody (Nab), titer of ADA positive samples
  • ORR [ Time Frame: Up to approximately 24 months from first patient in. ]
    Objective response rate (ORR) was assessed based on RECIST V1.1 criteria
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Official Title  ICMJE A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors
Brief Summary The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced or Metastatic Solid Tumors.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description:
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumors
Intervention  ICMJE
  • Drug: JS107
    JS107, i.v., q3w
  • Drug: Toripalimab
    Toripalimab i.v., q3w
Study Arms  ICMJE
  • Experimental: JS107
    Intervention: Drug: JS107
  • Experimental: JS107 combination with Toripalimab
    • Drug: JS107
    • Drug: Toripalimab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 14, 2022)
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2024
Estimated Primary Completion Date July 31, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The subjects voluntarily participated in the study with full informed consent and signed written informed consent form;
  2. Aged ≥18 years and ≤75 years when the subject signed the informed consent;
  3. Locally advanced unresectable or metastatic malignant solid tumors diagnosed histologically ;
  4. Provide past tumor samples or fresh tumor tissue biopsy samples;
  5. The physical status score is 0 or 1 on the Eastern Oncology Collaboration (ECOG) scale;
  6. The expected survival is ≥3 months;
  7. There should be at least one measurable lesion according to RECIST V1.1 evaluation criteria;
  8. Any adverse events and/or complications resulting from prior treatment, including surgery or radiation therapy, that have been adequately resolved to level 0 or 1 (according to the NATIONAL Cancer Institute Standard for General Terminology of Adverse Events (NCI-CTCAE 5.0) or to the level specified in the inclusion criteria; Any grade of hair loss/pigmentation and other long-term toxicity caused by treatment, except those that are irreversible and do not affect study dosing/compliance and patient safety at the discretion of the investigator;
  9. Good organ function;
  10. Within 7 days prior to the first dose, women of reproductive age must be confirmed as having a negative serum pregnancy test and consent to use effective contraception during the duration of study drug use and for 6 months after the last dose. Male patients with a female partner of reproductive age agreed to use effective contraception during the study drug use period and for 6 months after the last dose.

Exclusion Criteria:

  1. Prior treatment with drugs or other therapies targeting CLDN18.2;
  2. A history of severe allergic reactions to other monoclonal antibodies or to any component of JS107, or to other drugs or excipients involved in the trial protocol ;
  3. Received radiotherapy (except palliative radiotherapy for symptom control), chemotherapy, targeted therapy, endocrine therapy and other antitumor therapies, or other investigational drugs within 4 weeks before the administration of the first dose;
  4. Received any monoclonal antibody or antibody conjugate within 4 weeks prior to administration of the first study drug or within 5 half-lives (depend on whichever is shorter);
  5. Persons who have an immunodeficient disease or the other chronic immunosuppressive therapy, or who have received systemic immunomodulatory drugs (including, but not limited to, interferon or IL-2) within 14 days before first dose or within the 5 half-life of the drug (depend on whichever is longer), or received systemic glucocorticoid therapy (10mg daily of prednisone or equivalent glucocorticoids) or other systemic immunosuppressive therapy within 14 days before first dose;
  6. Received any live vaccine (e.g. influenza vaccine against infectious diseases, chickenpox vaccine, etc.) within 14 days before first dose;
  7. Serious infection (CTCAE> grade 2) occurred within 14 days before the first dose;
  8. Patients with other malignant tumors except for the tumor treated in the study within 5 years prior to the administration of the first study drug (exceptions included: cured malignancies that had not recurred within 3 years prior to study enrollment; Completely resected basal and squamous cell skin cancers; Complete resection of any type of carcinoma in situ, etc.);
  9. Major organ surgery was performed or significant trauma was present within 4 weeks before the first administration of the study drug;
  10. Weight loss 10% within 2 months before drug administration, or other indicators of severe malnutrition, or body mass index (BMI)<17.5 at the time of signing the informed consent.
  11. The following conditions were present within 6 months prior to the first study dose: myocardial infarction, severe/unstable angina, NYHA class 2 or higher cardiac insufficiency, clinically significant supraventricular or ventricular arrhythmia, and symptomatic congestive heart failure , hypertensive crisis, or hypertensive encephalopathy; patients with known hypertension, coronary artery disease, congestive heart failure not meeting the above criteria, or left ventricular ejection fraction <50% must be treated with optimal stabilization as determined by the treating physician medical plan;
  12. Pericardial effusion, pleural effusion or abdominal effusion with clinical symptoms, signs or requiring symptomatic treatment;
  13. Poorly controlled pain related;
  14. The presence of uncontrolled or symptomatic active central nervous system (CNS) metastases, which can be manifested by the onset of clinical symptoms, cerebral edema, spinal cord compression, carcinomatous meningitis, leptomeningeal disease, and/or progressive growth;
  15. Active infection, including tuberculosis (clinical diagnosis including clinical history, physical examination and imaging findings, as well as TB tests according to local medical routine), hepatitis B, hepatitis C or human immunodeficiency virus (HIV antibody positive);
  16. History of autoimmune disease;
  17. Idiopathic pulmonary fibrosis, drug-induced pneumonia, machine-induced pneumonia (bronchiolitis obliterans), radioactive pneumonia with clinical symptoms or requiring steroid treatment, active pneumonia, or other moderate to severe lung diseases that seriously affect lung function ;
  18. Pregnant or lactating women;
  19. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
  20. Have serious psychological or mental abnormality, which affects the compliance of the subject to participate in this clinical study;
  21. Participated in any other clinical trial within 28 days prior to the first administration of study drug;
  22. Other conditions deemed inappropriate for study participation by the investigator.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Ruihua Xu, M.D 86 020-87342479 xurh@sysucc.org.cn
Contact: Furong Liu, Medicie Postgraduate 86 020-87342479 liufr@sysucc.org.cn
Listed Location Countries  ICMJE China
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT05502393
Other Study ID Numbers  ICMJE JS107-001-I
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Shanghai Junshi Bioscience Co., Ltd.
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Shanghai Junshi Bioscience Co., Ltd.
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Ruihua Xu, M.D. Sun Yat-sen University
PRS Account Shanghai Junshi Bioscience Co., Ltd.
Verification Date July 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP